-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Estrella Immunopharma, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2021 to Q1 2024.
- Estrella Immunopharma, Inc. Operating Income (Loss) for the quarter ending March 31, 2024 was -$470K, a 82.9% increase year-over-year.
- Estrella Immunopharma, Inc. Operating Income (Loss) for the twelve months ending March 31, 2024 was -$3.53M, a 59.9% increase year-over-year.
- Estrella Immunopharma, Inc. annual Operating Income (Loss) for 2022 was -$1.57M, a 530% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)